These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 22502920)

  • 1. Deferasirox exposure induces reactive oxygen species and reduces growth and viability of myelodysplastic hematopoietic progenitors.
    Pullarkat V; Sehgal A; Li L; Meng Z; Lin A; Forman S; Bhatia R
    Leuk Res; 2012 Aug; 36(8):966-73. PubMed ID: 22502920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The iron chelator deferasirox affects redox signalling in haematopoietic stem/progenitor cells.
    Tataranni T; Agriesti F; Mazzoccoli C; Ruggieri V; Scrima R; Laurenzana I; D'Auria F; Falzetti F; Di Ianni M; Musto P; Capitanio N; Piccoli C
    Br J Haematol; 2015 Jul; 170(2):236-46. PubMed ID: 25825160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective toxicity towards myelodysplastic hematopoietic progenitors - another rationale for iron chelation in MDS.
    Fibach E; Rachmilewitz EA
    Leuk Res; 2012 Aug; 36(8):962-3. PubMed ID: 22633002
    [No Abstract]   [Full Text] [Related]  

  • 4. Iron overload impairs proliferation of erythroid progenitors cells (BFU-E) from patients with myelodysplastic syndromes.
    Hartmann J; Braulke F; Sinzig U; Wulf G; Maas JH; Konietschke F; Haase D
    Leuk Res; 2013 Mar; 37(3):327-32. PubMed ID: 23259989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
    Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD34+ cells from patients with myelodysplastic syndrome present different p21 dependent premature senescence.
    Xiao Y; Wang J; Song H; Zou P; Zhou D; Liu L
    Leuk Res; 2013 Mar; 37(3):333-40. PubMed ID: 23219618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox.
    Kikuchi S; Kobune M; Iyama S; Sato T; Murase K; Kawano Y; Takada K; Ono K; Kaneko Y; Miyanishi K; Sato Y; Hayashi T; Takimoto R; Kato J
    Free Radic Biol Med; 2012 Aug; 53(4):643-8. PubMed ID: 22705364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging.
    Messa E; Carturan S; Maffè C; Pautasso M; Bracco E; Roetto A; Messa F; Arruga F; Defilippi I; Rosso V; Zanone C; Rotolo A; Greco E; Pellegrino RM; Alberti D; Saglio G; Cilloni D
    Haematologica; 2010 Aug; 95(8):1308-16. PubMed ID: 20534700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mast cell growth factor (c-kit ligand) restores growth of multipotent progenitors in myelodysplastic syndrome.
    Glinsmann-Gibson B; Spier C; Baier M; Taetle R; Broudy VC; List AF
    Leukemia; 1994 May; 8(5):827-32. PubMed ID: 7514248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic inhibitory effects of deferasirox in combination with decitabine on leukemia cell lines SKM-1, THP-1, and K-562.
    Li N; Chen Q; Gu J; Li S; Zhao G; Wang W; Wang Z; Wang X
    Oncotarget; 2017 May; 8(22):36517-36530. PubMed ID: 28388554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GATA-1 transcription factor is up-regulated in bone marrow hematopoietic progenitor CD34(+) and erythroid CD71(+) cells in myelodysplastic syndromes.
    Maratheftis CI; Bolaraki PE; Voulgarelis M
    Am J Hematol; 2007 Oct; 82(10):887-92. PubMed ID: 17570514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their differentiation capacity.
    Jiménez-Solas T; López-Cadenas F; Aires-Mejía I; Caballero-Berrocal JC; Ortega R; Redondo AM; Sánchez-Guijo F; Muntión S; García-Martín L; Albarrán B; Alonso JM; Del Cañizo C; Hernández-Hernández Á; Díez-Campelo M
    Br J Haematol; 2019 Oct; 187(1):93-104. PubMed ID: 31172513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The oral iron chelator deferasirox inhibits NF-κB mediated gene expression without impacting on proximal activation: implications for myelodysplasia and aplastic anaemia.
    Banerjee A; Mifsud NA; Bird R; Forsyth C; Szer J; Tam C; Kellner S; Grigg A; Motum P; Bentley M; Opat S; Grigoriadis G
    Br J Haematol; 2015 Feb; 168(4):576-82. PubMed ID: 25271366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of stromal function, and its potential contribution to deregulation of hematopoiesis in the myelodysplastic syndromes.
    Tauro S; Hepburn MD; Bowen DT; Pippard MJ
    Haematologica; 2001 Oct; 86(10):1038-45. PubMed ID: 11602409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: a brief review.
    Guariglia R; Martorelli MC; Villani O; Pietrantuono G; Mansueto G; D'Auria F; Grieco V; Bianchino G; Lerose R; Bochicchio GB; Musto P
    Leuk Res; 2011 May; 35(5):566-70. PubMed ID: 21185078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective effects of deferasirox and N-acetyl-L-cysteine on iron overload-injured bone marrow.
    Shen JC; Zhang YC; Zhao MF
    Braz J Med Biol Res; 2017 Oct; 50(12):e6087. PubMed ID: 29069221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deferasirox has strong anti-leukemia activity but may antagonize theanti-leukemia effect of doxorubicin.
    Chang YC; Lo WJ; Huang YT; Lin CL; Feng CC; Lin HT; Cheng HC; Yeh SP
    Leuk Lymphoma; 2017 Sep; 58(9):1-12. PubMed ID: 28140713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo.
    Harima H; Kaino S; Takami T; Shinoda S; Matsumoto T; Fujisawa K; Yamamoto N; Yamasaki T; Sakaida I
    BMC Cancer; 2016 Aug; 16(1):702. PubMed ID: 27582255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The low viability of human CD34+ cells under acidic conditions is improved by exposure to thrombopoietin, stem cell factor, interleukin-3, or increased cyclic adenosine monophosphate levels.
    D'Atri LP; Etulain J; Romaniuk MA; Torres O; Negrotto S; Schattner M
    Transfusion; 2011 Aug; 51(8):1784-95. PubMed ID: 21332728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The iron chelator deferasirox induces apoptosis by targeting oncogenic Pyk2/β-catenin signaling in human multiple myeloma.
    Kamihara Y; Takada K; Sato T; Kawano Y; Murase K; Arihara Y; Kikuchi S; Hayasaka N; Usami M; Iyama S; Miyanishi K; Sato Y; Kobune M; Kato J
    Oncotarget; 2016 Sep; 7(39):64330-64341. PubMed ID: 27602957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.